Biokinetics and effects of barium sulfate nanoparticles

Part Fibre Toxicol. 2014 Oct 21:11:55. doi: 10.1186/s12989-014-0055-3.

Abstract

Background: Nanoparticulate barium sulfate has potential novel applications and wide use in the polymer and paint industries. A short-term inhalation study on barium sulfate nanoparticles (BaSO₄ NPs) was previously published [Part Fibre Toxicol 11:16, 2014]. We performed comprehensive biokinetic studies of ¹³¹BaSO₄ NPs administered via different routes and of acute and subchronic pulmonary responses to instilled or inhaled BaSO₄ in rats.

Methods: We compared the tissue distribution of ¹³¹Ba over 28 days after intratracheal (IT) instillation, and over 7 days after gavage and intravenous (IV) injection of ¹³¹BaSO₄. Rats were exposed to 50 mg/m³ BaSO₄ aerosol for 4 or 13 weeks (6 h/day, 5 consecutive days/week), and then gross and histopathologic, blood and bronchoalveolar lavage (BAL) fluid analyses were performed. BAL fluid from instilled rats was also analyzed.

Results: Inhaled BaSO₄ NPs showed no toxicity after 4-week exposure, but a slight neutrophil increase in BAL after 13-week exposure was observed. Lung burden of inhaled BaSO₄ NPs after 4-week exposure (0.84 ± 0.18 mg/lung) decreased by 95% over 34 days. Instilled BaSO₄ NPs caused dose-dependent inflammatory responses in the lungs. Instilled BaSO₄ NPs (0.28 mg/lung) was cleared with a half-life of ≈ 9.6 days. Translocated ¹³¹Ba from the lungs was predominantly found in the bone (29%). Only 0.15% of gavaged dose was detected in all organs at 7 days. IV-injected ¹³¹BaSO₄ NPs were predominantly localized in the liver, spleen, lungs and bone at 2 hours, but redistributed from the liver to bone over time. Fecal excretion was the dominant elimination pathway for all three routes of exposure.

Conclusions: Pulmonary exposure to instilled BaSO₄ NPs caused dose-dependent lung injury and inflammation. Four-week and 13-week inhalation exposures to a high concentration (50 mg/m³) of BaSO₄ NPs elicited minimal pulmonary response and no systemic effects. Instilled and inhaled BaSO₄ NPs were cleared quickly yet resulted in higher tissue retention than when ingested. Particle dissolution is a likely mechanism. Injected BaSO₄ NPs localized in the reticuloendothelial organs and redistributed to the bone over time. BaSO₄ NP exhibited lower toxicity and biopersistence in the lungs compared to other poorly soluble NPs such as CeO₂ and TiO₂.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Air Pollutants / analysis
  • Air Pollutants / toxicity*
  • Animals
  • Barium Radioisotopes
  • Barium Sulfate / administration & dosage
  • Barium Sulfate / analysis
  • Barium Sulfate / chemistry
  • Barium Sulfate / toxicity*
  • Dose-Response Relationship, Drug
  • Female
  • Half-Life
  • Inhalation Exposure / adverse effects*
  • Injections, Intravenous
  • Intestinal Absorption
  • Intestinal Elimination
  • Lung / chemistry
  • Lung / drug effects*
  • Lung / immunology
  • Lung / pathology
  • Male
  • Metal Nanoparticles / administration & dosage
  • Metal Nanoparticles / analysis
  • Metal Nanoparticles / chemistry
  • Metal Nanoparticles / toxicity*
  • Pneumonia / chemically induced*
  • Pneumonia / immunology
  • Pneumonia / metabolism
  • Pneumonia / pathology
  • Rats, Inbred WKY
  • Respiratory Mucosa / chemistry
  • Respiratory Mucosa / drug effects*
  • Respiratory Mucosa / immunology
  • Respiratory Mucosa / pathology
  • Respiratory Tract Absorption
  • Solubility
  • Tissue Distribution
  • Toxicity Tests, Acute
  • Toxicity Tests, Subchronic
  • Toxicokinetics

Substances

  • Air Pollutants
  • Barium Radioisotopes
  • Barium Sulfate